Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical selection criteria for treatment of HD IL2

From: High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome

Clinical Selection criteria:  
 • Histological diagnosis of clear-cell type metastatic renal cell carcinoma with measurable disease
 • Performance status 0–1
 • Prior-nephrectomy
 • No concomitant use of steroids
 • No evidence of active CNS involvement
 • No history of coronary artery disease or normal stress echocardiogram for patient older than 55-year-old of age.